Exozymes (EXOZ) Change in Accured Expenses (2023 - 2025)
Exozymes (EXOZ) posted quarterly Change in Accured Expenses of $330984.0 for Q4 2025, up 10.24% year-over-year from $300247.0 in Q4 2024, and up 1359.64% quarter-over-quarter from -$26276.0 in Q3 2025.
Exozymes (EXOZ) Change in Accured Expenses (2023 - 2025) Analysis & Trends
Exozymes (EXOZ) has reported Change in Accured Expenses for 3 consecutive years, with $330984.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Change in Accured Expenses rose 10.24% year-over-year to $330984.0; the TTM figure through Dec 2025 stood at $311085.0 (up 40.55% YoY), while the FY2025 annual figure was $311085.0, up 40.55% from the prior year.
- Change in Accured Expenses grew to $330984.0 in Q4 2025 per EXOZ's latest filing, from -$26276.0 in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $399357.0 in Q4 2023 and bottomed at -$405857.0 in Q2 2024.
- Historically, Change in Accured Expenses has averaged $103531.3 across 3 years, with a median of $147547.0 in 2025.
- On a YoY basis, Change in Accured Expenses climbed as much as 174.42% in 2025 and fell as far as 109.62% in 2025.
- Exozymes' Change in Accured Expenses stood at $399357.0 in 2023, then dropped by 24.82% to $300247.0 in 2024, then rose by 10.24% to $330984.0 in 2025.
- Business Quant data shows EXOZ's Change in Accured Expenses at $330984.0 in Q4 2025, -$26276.0 in Q3 2025, and -$141170.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Exozymes | 62.35 Mn | 62.35 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 330,984.00 |
| Dec 31, 2025 | 330,984.00 |
| Sep 30, 2025 | -26,276.00 |
| Sep 30, 2025 | -26,276.00 |
| Jun 30, 2025 | -141,170.00 |
| Jun 30, 2025 | -141,170.00 |
| Mar 31, 2025 | 147,547.00 |
| Mar 31, 2025 | 147,547.00 |
| Dec 31, 2024 | 300,247.00 |
| Dec 31, 2024 | 300,247.00 |
| Sep 30, 2024 | 273,184.00 |
| Sep 30, 2024 | 273,184.00 |
| Jun 30, 2024 | -405,857.00 |
| Jun 30, 2024 | -405,857.00 |
| Mar 31, 2024 | 53,766.00 |
| Mar 31, 2024 | 53,766.00 |
| Dec 31, 2023 | 399,357.00 |
| Dec 31, 2023 | 399,357.00 |